v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (194,423) $ (67,251)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 69,254 74,137
Non-cash interest 63,866 12,753
Amortization of deferred financing costs 5,097 1,328
Losses from investments in investees 12 7
Equity-based compensation – employees and non-employees 7,797 7,983
Impairment of Intangible Assets 1,007 0
Realized gain on disposal of fixed assets and sales of equity securities (3,846) (9,489)
Change in fair value of equity securities and derivative instruments 1,447 (94,626)
Inducement expense and loss on debt conversion 32,647 725
Deferred income tax (benefit) provision (4,850) 7,695
Gain on sale of assets (101,576) (121,493)
Changes in assets and liabilities:    
Accounts receivable, net 23,504 15,680
Inventory, net (5,291) 6,452
Other current assets and prepaid expenses (1,283) (8,395)
Other assets (98) 564
Accounts payable 2,843 (6,527)
Foreign currency measurement (4,665) (3,575)
Accrued expenses and other liabilities (44,063) 44,952
Net cash used in operating activities (152,621) (139,080)
Cash flows from investing activities:    
Investments in investees (7,665) 0
Proceeds from sale of equity securities 51,655 46,731
Purchase of marketable securities 0 (1,454)
Proceeds from the sale of property, plant and equipment 194 169
Capital expenditures (9,612) (19,597)
Proceeds from Labcorp sales including escrow released 197,770 210,378
Net cash provided by investing activities 232,342 236,227
Cash flows from financing activities:    
Issuance of 3.00% convertible senior notes, net (including related parties) 0 230,000
Issuance of 2044 Notes 0 250,000
Debt issuance costs 0 (13,385)
Share repurchase (33,533) (73,759)
Proceeds from the exercise of common stock options (123) (208)
Repurchase of 2029 Convertible Notes (62,208) (4,881)
Borrowings on lines of credit 24,505 448,459
Repayments of lines of credit (28,184) (465,301)
Settlement of convertible notes (174) (146,287)
Net cash (provided by) used in financing activities (99,717) 224,638
Effect of exchange rate changes on cash, cash equivalents and restricted cash 3,255 2,399
Net decrease (increase) in cash, cash equivalents and restricted cash (16,741) 324,184
Cash, cash equivalents and restricted cash at beginning of period 445,615 95,881
Cash, cash equivalents and restricted cash at end of period 428,874 420,065
SUPPLEMENTAL INFORMATION:    
Interest paid 30,206 12,982
Income taxes paid, net of refunds 20,624 3,801
Non-cash financing:    
Common stock options, warrants, and restricted stock units surrendered in net exercise $ 213 $ 208

Source